跳至主要内容
临床试验/NCT01926821
NCT01926821招募中1 期

The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer

Asan Medical Center1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
200
试验地点
1
主要终点
Quality of life

研究概览

简要总结

The impact of sonifilan on the quality of life in patients with cervical cancer during radiation or chemoradiation therapy

  1. Primary endpoint : Quality of life
  2. Secondary endpoint : complications related to Sonifilan, treatment effect of Sonifilan

详细描述

Study design Prospective randomized controlled trial

Study period Protocol registration approval date - may/31/2016

Study drug Sonifilan(Sizofiran)

Study population

  1. Cervical cancer FIGO stage IA2-IVA patients will be participated.
  2. Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma
  3. age 20-75 year

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Cervical cancer FIGO stage IA2 - IVA
  • Histologic type : SCC, Adenocarcinoma, Adenosquamous carcinoma
  • GOG performance status 0-2

排除标准

  • past radiation therapy history
  • Neuroendocrine carcinoma
  • concurrent other cancer
  • uncontrolled medical disease
  • ulcerative disease history
  • current pregnancy and lactation

研究组 & 干预措施

sonifilan

Experimental

Group who get sonifilan

干预措施: Sonifilan (Drug)

结局指标

主要结局

Quality of life

时间窗: 3 year

life quality assessment by filling out EORTC QOQ-C30, CX24, SF-36, FSFI pre-/on-/post-study

次要结局

  • Complications of drug, treatment effects(3 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jong-Hyeok Kim

Professor

Asan Medical Center

研究点 (1)

Loading locations...

相似试验